NYSE:SLS - Galena Biopharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.47 -0.15 (-9.26 %)
(As of 07/18/2018 04:00 PM ET)
Previous Close$1.62
Today's Range$1.43 - $1.64
52-Week Range$1.43 - $17.70
Volume780,900 shs
Average Volume376,618 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Develop biopharmaceuticals

Receive SLS News and Ratings via Email

Sign-up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Biotechnology
Sub-IndustryN/A
SectorHealth Technology
SymbolNYSE:SLS
CUSIPN/A
WebN/A
Phone(917) 438-4353

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares6,660,000
Market Cap$0.00

The Truth About Cryptocurrencies

Galena Biopharma (NYSE:SLS) Frequently Asked Questions

What is Galena Biopharma's stock symbol?

Galena Biopharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "SLS."

What price target have analysts set for SLS?

1 brokers have issued twelve-month target prices for Galena Biopharma's shares. Their predictions range from $11.00 to $11.00. On average, they anticipate Galena Biopharma's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 648.3% from the stock's current price. View Analyst Ratings for Galena Biopharma.

What is the consensus analysts' recommendation for Galena Biopharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galena Biopharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Galena Biopharma's key competitors?

Who are Galena Biopharma's key executives?

Galena Biopharma's management team includes the folowing people:
  • Angelos M. Stergiou, President, Chief Executive Officer & Director
  • Aleksey N. Krylov, Chief Financial Officer, Treasurer & Director
  • Nicholas J. Sarlis, Director, Chief Medical Officer & Senior VP
  • Barbara A. Wood, Secretary, Executive VP & General Counsel
  • Gregory M. Torre, Director, Chief Regulatory Officer & Senior VP

Has Galena Biopharma been receiving favorable news coverage?

Media stories about SLS stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Galena Biopharma earned a media sentiment score of 0.07 on Accern's scale. They also gave news stories about the company an impact score of 45.56 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Galena Biopharma?

Shares of SLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galena Biopharma's stock price today?

One share of SLS stock can currently be purchased for approximately $1.47.

How can I contact Galena Biopharma?

The company can be reached via phone at (917) 438-4353.


MarketBeat Community Rating for Galena Biopharma (NYSE SLS)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  7 (Vote Outperform)
Underperform Votes:  10 (Vote Underperform)
Total Votes:  17
MarketBeat's community ratings are surveys of what our community members think about Galena Biopharma and other stocks. Vote "Outperform" if you believe SLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.